A patent from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. has divulged new antibody-drug conjugates comprising antibodies covalently linked to N-myristoyltransferase 1 (NMT1) inhibitors for potential use in the treatment of cancer.
Clinical responses to BCMA- or GPRC5D-directed T-cell engagers in relapsed/refractory multiple myeloma (MM) are often limited by disease relapse and antigen escape, underscoring the need for dual-targeting strategies that enhance durability while mitigating cytokine-driven toxicity.
The advent of antibody-drug conjugates (ADCs) changed targeted cancer therapy by enabling the delivery of cytotoxic agents to cancer cells. Topoisomerase I inhibitors are commonly used as payloads in TROP2-directed ADCs, but they are linked to toxicity and emerging resistance. Degrader-antibody conjugates (DACs) go beyond conventional cytotoxic payloads by combining antigen targeting and selective protein degradation.
At the recently concluded congress of the European Hematology Association, researchers at Cogent Biosciences Inc. presented preclinical data on CGT-1145, a JAK2 V617F-mutant-selective inhibitor designed to preferentially target the mutant kinase while sparing wild-type JAK2.
Harnessing an oncolytic signal and redirecting it against the tumor itself could be developed as a selective strategy for certain cancer types, as occurs with ErbB hyperactivity, a form of signaling that drives many carcinomas. Inspired by this idea, scientists at Stanford University have engineered a virus that replicates only in ErbB-hyperactive ovarian cancer cells. This allowed them to precisely kill this specific tumor population, achieving greater efficacy and safety than previous oncolytic viruses.
Sichuan Huiyu Pharmaceuticals Co. Ltd. and Sichuan Huiyu Seacross Pharma Technology Ltd. have patented new Son of sevenless homolog 1 (SOS1) inhibitors potentially useful for the treatment of cancer and Noonan syndrome.
Iteos Belgium SA has synthesized new tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or PTPN2 inhibitors potentially useful for the treatment of cancer.
Ensem Therapeutics Inc. has disclosed new tetracyclic GTPase KRAS mutant inhibitors, particularly G12V mutant inhibitors, potentially useful for the treatment of cancer.
Researchers from Peking University and Bristar Immunotech Ltd. recently presented the development of a synthetic T-cell receptor and antigen receptor-T (STAR-T) cell therapy targeting leukocyte immunoglobulin-like receptor B4 (LILRB4) for acute myeloid leukemia (AML).
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable feature of aging. Certainly, it is near universal in those older than 60. CH is not itself a disease, but 1%-2% of CH cases progress to acute myeloid leukemia, and it raises the risk of some other types of cancer as well. A total of eight genes are responsible for 95% of CH cases, George Vassiliou told the audience in Saturday’s plenary session at the 2026 Annual Congress of the European Hematology Association (EHA 2026).
RSS
